Core Viewpoint - The company is utilizing idle funds for structured deposits and purchasing financial products to enhance capital efficiency and returns, while ensuring normal operational liquidity is maintained [2][3]. Group 1: Basic Information on Entrusted Wealth Management - The company plans to use up to RMB 500 million of idle self-owned funds for structured deposits and financial products from banks, securities firms, or trust companies [2]. - The decision was approved by the company's board and shareholders, with details disclosed in specific announcements [2]. Group 2: Progress and Risk Situation of Entrusted Wealth Management - From November 7, 2025, to the date of the announcement, the company has invested RMB 220 million in various financial products, including government bond reverse repos and products from several banks and securities firms [2][3]. Group 3: Impact on the Company and Risk Control Measures - The investment of idle funds is conducted without affecting the company's main business, financial status, or cash flow, thereby improving the efficiency and returns of idle funds [2]. - The company has established a risk control framework for purchasing financial products, ensuring effective execution and compliance with approval processes [3]. - The finance department will monitor the investment and take necessary actions if risks to fund safety are identified, with oversight from independent directors and the supervisory board [3][4].

Core Viewpoint - The company and its subsidiary, Yangzhou Bangjie New Energy Technology Co., Ltd., are undergoing a pre-restructuring process due to financial difficulties, with the aim of preserving the company's value and restoring its profitability [2][6]. Group 1: Bankruptcy Restructuring Process - On September 4, 2025, the company disclosed that Yangzhou Bangjie was applied for pre-restructuring by a creditor due to its inability to repay debts and lack of repayment capacity, despite having restructuring value [2]. - On September 16, 2025, the court accepted the pre-restructuring application [2]. - On November 18, 2025, the court appointed a joint management team for the pre-restructuring phase [2]. - On November 27, 2025, the management team initiated the debt claim process for Yangzhou Bangjie [3]. - On December 11, 2025, the court allowed Yangzhou Bangjie to borrow funds during the pre-restructuring period to maintain its asset value [3]. - On February 3, 2026, the court accepted the restructuring application from the creditor [3]. Group 2: Management Responsibilities - The appointed management team is responsible for taking over the debtor's assets, investigating the financial status, and managing the debtor's internal affairs [4][5]. - The management team must report to the court and be supervised by the creditors' meeting and committee [4]. Group 3: Impact on the Company - Yangzhou Bangjie is a core subsidiary and an important platform for the company's photovoltaic business; successful restructuring could improve the company's financial structure [6]. - The financial liabilities of Yangzhou Bangjie amount to approximately 630 million yuan, with the company providing guarantees, which poses a risk of fulfilling these obligations [7]. - The company has invested 505 million yuan in Yangzhou Bangjie, which may not be recoverable due to the restructuring [7]. - The company has provided around 650 million yuan in financial support to Yangzhou Bangjie, making it a significant creditor, which could lead to risks of uncollectible receivables [7]. - The restructuring process may involve additional risks related to debt confirmation and the final restructuring plan approved by the court [7]. Group 4: Financial Performance - The company reported a projected net asset of between -900.1551 million yuan and -600.1551 million yuan for the end of 2025, with a projected net loss of between -1.2 billion yuan and -900 million yuan for the same period [10]. - The main business segments include seamless clothing and photovoltaic businesses, with seamless clothing generating 620 million yuan in revenue for 2024, accounting for 56.06% of total revenue [11]. - The photovoltaic business generated 452 million yuan in revenue for 2024, accounting for 40.86% of total revenue [11].

Core Viewpoint - The company has received ANDA approval from the FDA for its sodium selenite injection, which is expected to enhance its international product pipeline and positively impact its operational performance if successfully marketed in the U.S. [1][4] Group 1: Drug Information - Drug Name: Sodium Selenite Injection [2][6] - Indication: For adult and pediatric patients requiring parenteral nutrition, serving as a source of selenium when oral or enteral nutrition is not feasible, insufficient, or contraindicated [1][2] - Dosage Form: Injection [6] - Specification: 600 mcg/10 mL [6] - ANDA Number: 219472 [6] Group 2: Approval Details - The ANDA application for sodium selenite injection was approved by the FDA on February 4, 2026 [2] - The reference formulation is held by AMERICAN REGENT INC, which received FDA approval for its product, SELENIOUS ACID, on April 30, 2019 [2] - Currently, five other companies have also received approval for sodium selenite injection in the U.S. market [2] Group 3: Financial Investment - The company has invested approximately RMB 6.5605 million in the research and development of the sodium selenite injection project [3] Group 4: Impact on Company - The newly approved product enriches the company's international product pipeline and strengthens its market presence [4] - Successful market entry in the U.S. is anticipated to have a positive effect on the company's operational performance [4]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 江苏苏利精细化工股份有限公司（以下简称"公司"）于 2025年4月22日召开第五届董事会第四次会议及 第五届监事会第二次会议，审议通过了《关于使用部分闲置募集资金及自有资金进行现金管理的议 案》，同意公司使用额度不超过3.00亿元的闲置募集资金购买安全性高、流动性好、有保本约定的理财 产品或存款类产品，投资产品的期限不超过12个月。公司董事会、监事会及保荐机构已分别对此发表了 同意的意见。具体内容详见公司于2025年4月24日在指定信息披露媒体上披露的《江苏苏利精细化工股 份有限公司关于使用部分闲置募集资金及自有资金进行现金管理的公告》（公告编号：2025-038）。 特此公告。 江苏苏利精细化工股份有限公司 董事会 2026年2月5日 上述理财产品的详细购买情况请见公司在上海证券交易所网站（www.sse.com.cn）披露的《江苏苏利精 细化工股份有限公司关于使用部分闲置募集资金进行现金管理的进展公告》（公告编号：202 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 特别提示 安徽林平循环发展股份有限公司（以下简称"林平发展"、"发行人"或"公司"）首次公开发行人民币普通 股（Ａ股）（以下简称"本次发行"）并在主板上市的申请已经上海证券交易所（以下简称"上交所"）上 市审核委员会审议通过，并已经中国证券监督管理委员会同意注册（证监许可〔２０２５〕３０１９ 号）。 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"或"保荐人（主承销商）"）担任本次发 行的保荐人（主承销商）。发行人股票简称为"林平发展"，扩位简称为"林平发展"，股票代码为"６０ ３２８４"。 本次发行采用网下向符合条件的网下投资者询价配售（以下简称"网下发行"）与网上向持有上海市场非 限售Ａ股股份和非限售存托凭证市值的社会公众投资者定价发行（以下简称"网上发行"）相结合的方式 进行。 发行人和保荐人（主承销商）根据初步询价结果，综合评估公司合理投资价值、可比公司二级市场估值 水平、所属行业二级市场估值水平等方面，充分考虑网下投资者有效申购倍数、市场情况、募集资金需 求及承销风险等因素，协商确定本次发行价格为３７．８８元／股，发行数量１，８８５．３７０ ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：601665 证券简称：齐鲁银行 公告编号：2026-004 齐鲁银行股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ■ 注：1、非经常性损益根据《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》（2023 年修订）的规定计算。 2、基本每股收益、加权平均净资产收益率根据《公开发行证券的公司信息披露编报规则第9号一一净资 产收益率和每股收益的计算及披露》（2010年修订）的规定计算。加权平均净资产收益率同比下降主要 是本行可转换公司债券转为普通股股票的摊薄影响。 3、"贷款总额""存款总额"均不包含应计利息。 4、截至2025年末，本行已宣告尚未发放的2025年度中期现金股利7.45亿元已反映在2025年度财务报表 中。 二、经营业绩和财务状况情况说明 2025年，本行紧紧围绕中央决策部署和省市工作安排，按照"稳中求进、以进促稳，改革转型、协同发 力，守正创新、强基固本"的总体工作思路，持续夯实发展基础，加快推进转型 ...

证券代码：603266 证券简称：天龙股份 公告编号：2026-006 宁波天龙电子股份有限公司关于上海证券交易所 对公司资产收购事项的监管工作函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、摊薄上市公司的即期回报的风险。本次交易完成后，苏州豪米波技术有限公司（以下简称"苏州豪米 波"、"标的公司"）将成为上市公司的控股子公司。苏州豪米波短期内尚处于亏损状态，将导致上市公 司未来2-3年业绩下滑的风险，摊薄上市公司的即期回报。苏州毫米波未来的盈利预测系根据行业发展 趋势及在手订单、预计项目情况预测得出，若出现行业、政策、市场环境变化及标的公司自身研发和经 营不达预期的情况，将持续对上市公司的合并净利润造成负向影响。 2、商誉减值的风险。由于本次交易系非同一控制下的企业合并，根据《企业会计准则》规定，本次交 易完成后，上市公司将确认约1.8亿元的商誉，金额较大。如苏州毫米波未来经营状况恶化，则存在商 誉减值的风险，从而对上市公司当期损益造成不利影响。 3、业绩承诺无法实现的风险。苏州豪米波创始人 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 注册资本：人民币20,000万元整 成立日期：2016年10月13日 一、交易概述 因业务发展需要，山东步长制药股份有限公司（以下简称"公司"或"步长制药"）控股子公司上海合璞医 疗科技有限公司（以下简称"上海合璞"）股东王宝才拟将其未实缴的上海合璞0.05%股权以0元交易价格 转让给赵晓刚、拟将其未实缴的上海合璞0.025%股权以0元交易价格转让给程锴。公司同意放弃优先受 让权，交易完成后，公司持有上海合璞71.30%股权不变。具体内容详见公司2025年9月17日披露于上海 证券交易所网站（www.sse.com.cn）的《关于拟放弃优先受让控股子公司股权暨关联交易的公告》（公 告编号：2025-181）。 二、本次交易的进展 近日，上海合璞已完成工商变更登记手续。变更后的相关信息如下： 名称：上海合璞医疗科技有限公司 类型：有限责任公司（外商投资企业与内资合资） 法定代表人：胡昂 山东步长制药股份有限公司董事会 2026年2月5日 住所：上海市奉贤区海湾旅游区莘奉公路4936 ...

一、本次限售股上市类型 2017年11月30日，南京康尼机电股份有限公司（以下简称"康尼机电"或"公司"）收到中国证券监督管理 委员会（以下简称"中国证监会"）核发的《关于核准南京康尼机电股份有限公司向廖良茂等发行股份购 买资产并募集配套资金的批复》（证监许可[2017]2149号），核准公司向廖良茂等16位自然人及东莞市 众旺昕股权投资合伙企业（有限合伙）等4家机构发行股份购买相关资产。 根据中国证券登记结算有限责任公司上海分公司于2017年12月6日出具的《证券变更登记证明》，康尼 机电已于2017年12月6日办理完毕本次发行股份及支付现金购买资产的新增股份登记申请，新增股份数 量为157,292,234股（有限售条件的流通股），其中向廖良茂发行50,590,801股股份、向田小琴发行 3,514,535股股份、向梁炳基发行15,090,748股股份、向刘晓辉发行6,793,299股股份、向王赤昌发行 5,509,809股股份、向曾祥洋发行3,307,814股股份、向胡继红发行3,307,814股股份、向孔庆涛发行 3,307,814股股份、向邓泽林发行2,754,902股股份、向苏金贻发行2,424,3 ...

Group 1 - The core point of the announcement is the progress of the 2026 employee stock ownership plan, which has been approved by the board and shareholders, with 192 employees participating and a total of 62,790,000 shares subscribed [1][2][3] - The company has opened bank accounts and securities accounts for the employee stock ownership plan, and the subscription funds have been paid and verified [1][2] - As of the announcement date, the company has not yet purchased any shares under the 2026 employee stock ownership plan [1][2] Group 2 - The company plans to repurchase shares using its own funds through centralized bidding, with a total repurchase amount between 30 million and 50 million RMB, and a maximum repurchase price of 15 RMB per share [5][8] - The repurchase is intended for the implementation of the employee stock ownership plan or equity incentives, and any unutilized repurchased shares will be canceled after 36 months [5][8] - As of the end of January 2026, the company has not yet conducted any share repurchases [6][8] Group 3 - The company has established a dedicated securities account for the share repurchase, which will only be used for this purpose [28] - The company will continue to disclose information regarding the progress of the share repurchase in accordance with relevant laws and regulations [29][30]